|
|
|
|
Ortho Clinical Diagnostics Holdings Plc (OCDX) |
|
Price: $0.0000
$0.00 
%
|
| Day's High:
| 0.00
| Week Perf:
|
|
| Day's Low: |
$ 0.00 |
30 Day Perf: |
|
| Volume (M): |
0 |
52 Wk High: |
$ 0.00 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
| Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
479 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
-7 |
| Net Income (TTM) (Millions $) |
54 |
| Cash Flow (TTM) (Millions $) |
119 |
| Capital Exp. (TTM) (Millions $) |
72 |
Ortho Clinical Diagnostics Holdings Plc
Company Address: 1001 Route 202 Raritan 8869 NJ
Company Phone Number: 218-8000 Stock Exchange / Ticker: NASDAQ OCDX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Oncocyte Corporation
Oncocyte Corporation, a leading player in the In Vitro and In Vivo Diagnostic Substances industry, recently released its financial results for the third quarter of 2023. Despite reporting a significant increase in revenue compared to the same period last year, the company witnessed a widening of its losses. This article will outline the key facts from Oncocyte Corporation's financial results and provide context to better understand the company's performance in the industry.
Revenue Growth and Comparisons:
Oncocyte Corporation announced an impressive year-on-year revenue advancement of 946.341% in the third quarter of 2023, reaching $0.43 million. This growth significantly outperformed its industry peers, who reported an aggregated 11.10% top-line advance during the same period. However, it is important to note that the company's revenue deteriorated by -7.343% from the previous reporting season, where it recorded $0.46 million in revenue.
|
|
Volitionrx Limited
Volitionrx Limited, a biomedical company that specializes in blood-based diagnostics, experienced a significant increase in its stock value over the past week and month. However, despite robust revenue growth, the company continues to face challenges. This article delves into Volitionrx Limited's recent financial results and analyzes how these factors may impact the company's future prospects.
Impressive Revenue Growth:
Volitionrx Limited reported a remarkable year-on-year revenue increase of 405.016% to $0.17 million in the most recent fiscal period. This surge indicates a strong demand for the company's blood-based diagnostic solutions. Such exponential revenue growth demonstrates a positive market reception of Volitionrx's products and services.
|
|
Navidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals Inc (NAVB) has recently reported its financial results for the fiscal time-frame of July to September 2023. While the company did incur losses of $-0.02 per share during this period, it is worth noting the significant improvement compared to a loss of $-0.25 per share in the same quarter last year. Furthermore, earnings per share fell from $0.12 per share in the previous quarter, indicating a slight setback.
Although the revenue remained stagnant at $0.00 million, it is important to recognize that this figure was also consistent with the previous year's comparable quarter. Additionally, the revenue remained unchanged sequentially, indicating stability in the company's financial performance.
|
|
Aspira Women S Health Inc
Aspira Women's Health Inc, a leading healthcare company focused on women's health, recently released its financial results for the third quarter of 2023. The company reported a significant increase in the shortfall per share compared to the same period last year and the preceding reporting season. For the financial third quarter of 2023, AWH recorded a shortfall of $-0.48 per share, which is higher than the $-0.04 per share reported a year ago and the $-0.28 per share from the preceding reporting season.
In terms of revenue, Aspira Women's Health Inc experienced growth in comparison to the same reporting season a year ago, with a 6.998% increase, reaching $2.22 million from $2.07 million. However, the sequential revenue showed a deterioration of -11%, falling from $2.49 million in the previous reporting season.
|
|
Alpha Teknova Inc
In a recent announcement, Alpha Teknova, Inc. (Teknova) revealed its plans to raise up to $22.9 million through a registered direct offering and private placement. The funds raised will be used to accelerate research and development of life-saving therapies, vaccines, and molecular diagnostics. This strategic move aims to strengthen Teknova's position in the market and support the advancement of life-saving treatments.
Under the definitive agreements, Teknova will issue and sell up to 1,086,485 shares of its common stock in a registered direct offering at a purchase price of $1.85 per share. Additionally, the company has entered into an agreement to sell an additional 11,299,993 shares of common stock at the same purchase price in a private placement. The pricing of the shares in both offerings adheres to Nasdaq rules, based on the consolidated closing bid price.
|
| Per Share |
Current |
| Earnings (TTM) |
0.25 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
0.25 $ |
| Cash |
0.59 $
|
| Book Value |
0.93 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
0.25 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
0.25 $ |
| Cash |
0.59 $
|
| Book Value |
0.93 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights
reserved. This site uses cookies to make your browsing experince better. By
using this site, you agree to the Terms of Service and Privacy Policy - UPDATED
(Read about our Privacy Policy)
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
